B cell malignancies
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies
... Abstract: The expectations of nanoparticle (NP)-based targeted drug delivery systems in cancer, when compared with convectional therapeutic methods, are greater efficacy and reduced drug side effects due to specific ...
11
B-cell malignancies: capture-sequencing strategies for identification of gene rearrangements and translocations into immunoglobulin gene loci
... different B-cell neoplasms, the normal cellular counterparts they arise from, and the main translocations involving the iGH locus they harbor (the disease-defining translocations are shown in ...mature ...
13
RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B cell malignancies: study protocol for a randomized controlled trial
... refractory B-cell malignancies is active and safe prior to future phase II/III ...enhanced B-cell depletion and increased infiltration of myeloid cells with the addition of varlilumab ...
14
Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications
... induces cell death, the find- ing that TERT, besides maintaining telomere integrity, also plays a critical role in the establishment of EBV latency and in preventing the EBV lytic cycle ...induces cell ...
7
Targeted DNA vaccines eliciting crossreactive anti idiotypic antibody responses against human B cell malignancies in mice
... with B cell ...expressed B cell receptors (BCR) are called stereotyped ...HCV-associated B cell malignancies, such as MALT lymphomas [21-23] and Chronic Lymphocytic ...
12
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
... of B-cell malignancies on the B-cell receptor (BCR) signaling path- way has led to the development of novel orally-bioavailable small-molecule inhibitors of several kinases downstream ...
6
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
... T cell activation against either the recipient MHC antigens or minor histocom- patibility antigens, resulting in an excess of cytokines, in- cluding TNF-α and IFN-γ [25, ...CAR-T cell therapy. Accordingly, ...
8
Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
... with B cell malignancies is relevant to patients with RA, because rela- tively few patients with RA have been treated with ritux- ...with B cell malignan- cies and considers the ...
5
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
... against B cell lines and primary malignant B cells from patients in the presence or in absence of purified NK cells isolated from healthy ...a B cell depletion model consisting of SCID ...
13
Heterogeneity of Toll like receptor 9 signaling in B cell malignancies and its potential therapeutic application
... cells, B-cell malignancies arising from different stages of B cell development also express TLR9 ...of B-cell malignancies are different from normal B cells ...
10
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
... of B-cell malignancies in comparison with other kinase inhibitors targeting B-cell- receptor signaling, in particular with strictly isoform-δ-selective ...exhibits ...
14
Lamin B1 regulates somatic mutations and progression of B cell malignancies
... in B-cell ...of B-cell malignancies showing decreasing LMNB1 staining with increasing ...of B-cell natural development in secondary lymphoid ...naive B cells ...
13
Generation of CD20-specific TCRs for TCR gene therapy of CD20 low B-cell malignancies insusceptible to CD20-targeting antibodies
... primary B-cell malignancies such as ALL, CLL and MCL was ...primary B-cell leukemia. Moreover, lysis was also observed for ALL cell-lines that lacked sufficient cell ...
17
Engaging the lysosomal compartment to combat B cell malignancies
... with B cell ...dent B cell lymphoma cell death in vitro and show superior efficacy as com- pared with rituximab in eradicating target cells in mouse models are emerg- ing as the next ...
5
Ibrutinib for B cell malignancies
... relapsed/refractory B-cell malignancies, including non-Hodgkin’ s lymphoma, CLL, and Waldenstrom’s macro- globulinemia ...across B-cell histolo- ...
7
Toll-like receptors in the pathogenesis of human B cell malignancies
... in B-cell activation, maturation and memory and may be involved in the pathogenesis of B-cell ...of B-cell lymphomas has gained much ...normal B cell functioning ...
10
Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis
... malignant B cells but not to other normal myeloid, erythroid, megakaryocytic, or multilineage bone marrow progenitor cells ...against B-cell ...refractory B cell ...T cell ...
11
Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies
... The human cancer cell lines, SKM-1, Ramos and Hs 505.T were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA). The FLT3-ITD- expressing line, MV4-11, was provided by Dr. Anthony Letai, ...
11
Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200
... 41. Hegde UP, Mukherji B. Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. Cancer Immunol Immunother. Epub 2017 May 11. 42. ...
9
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies
... We [22] and others [23] have identified novel alter- native CD20 transcripts, fully matching the MS4A1 sequence, except for 501 bp (from nucleotides 111–612, starting +1 of the ATG codon) flanked by the cryptic acceptor ...
15